Diligence memo · auto-generated · as of July 2, 2026
VerImmune, Inc.
VerImmune, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
VerImmune, Inc. operates in Biotechnology, based in BETHESDA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
VerImmune, Inc. has raised $5.9M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.5M on 2024-08-27.
Most recent recorded round closed around 2024-08-27.
Valuation (modeled)modeled
Provath models VerImmune, Inc. at approximately $22M (range $4.9M–$46M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.49× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 29 months.
Last raise 22 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round stepped up 3.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 47% of Biotechnology peers (4293 compared).
Modeled value ranks above 30% of those peers.
Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.